BIAF - Bioaffinity Technologies Inc
NYSE * Health Care * Life Sciences Tools & Services
$1.31
$-0.06 (-4.38%)
About Bioaffinity Technologies Inc
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
BIAF Key Statistics
Market Cap
$6.16M
P/B Ratio
0.69
EPS
$-13.83
Revenue Growth
-0.4%
Profit Margin
-2.2%
Employees
57
How BIAF Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
#6
of 6
Growth Rank
#6
of 6
Size Rank
#6
of 6
Bioaffinity Technologies Inc Company Information
- Headquarters
- Texas; U.S.A
- Website
- www.bioaffinitytech.com
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services